Shoulder Innovations (NYSE:SI) COO Matthew Fraser Ahearn Sells 4,144 Shares

Shoulder Innovations, Inc. (NYSE:SI) COO Matthew Fraser Ahearn sold 4,144 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $18.84, for a total value of $78,072.96. Following the transaction, the chief operating officer directly owned 269,176 shares of the company’s stock, valued at $5,071,275.84. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Matthew Fraser Ahearn also recently made the following trade(s):

• On Friday, June 12th, Matthew Fraser Ahearn sold 15,856 shares of Shoulder Innovations stock. The stock was sold at an average price of $18.68, for a total value of $296,190.08.

Shoulder Innovations Stock Up 3.6%

SI stock opened at $18.78 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 11.81 and a quick ratio of 10.04. The stock has a market capitalization of $389.40 million and a P/E ratio of -0.11. The business has a 50-day moving average of $14.64 and a 200-day moving average of $14.40. Shoulder Innovations, Inc. has a fifty-two week low of $10.92 and a fifty-two week high of $19.79.

Shoulder Innovations (NYSE:SI) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.03. Shoulder Innovations had a negative return on equity of 35.11% and a negative net margin of 81.78%.The company had revenue of $16.71 million during the quarter. On average, sell-side analysts anticipate that Shoulder Innovations, Inc. will post -1.67 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SI has been the subject of several recent research reports. BTIG Research increased their price target on Shoulder Innovations from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Piper Sandler reissued an “overweight” rating and set a $19.00 price target (up from $18.00) on shares of Shoulder Innovations in a research report on Friday, May 8th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $21.00.

Institutional Trading of Shoulder Innovations

Several institutional investors and hedge funds have recently bought and sold shares of SI. Rhumbline Advisers bought a new stake in Shoulder Innovations in the third quarter valued at approximately $54,000. TimesSquare Capital Management LLC bought a new stake in Shoulder Innovations in the third quarter valued at approximately $4,799,000. Vanguard Group Inc. bought a new stake in Shoulder Innovations in the third quarter valued at approximately $1,836,000. Readystate Asset Management LP bought a new stake in Shoulder Innovations in the third quarter valued at approximately $511,000. Finally, Monashee Investment Management LLC bought a new stake in Shoulder Innovations in the third quarter valued at approximately $502,000.

Shoulder Innovations Company Profile

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.